Market Overview

Credit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed Trial

Share:
Credit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed Trial

Edge Therapeutics Inc (NASDAQ: EDGE) closed down 87 percent Wednesday and continued to decline Thursday after announcing layoffs, the discontinuation of its Phase 3 NEWTON 2 study and the evaluation of its next steps. 

Even now, Credit Suisse considers Edge overvalued.

The Rating

Analyst Martin Auster downgraded the stock from Outperform to Underperform and bulldozed the price target from $17 to $1.

The Thesis

Edge announced that interim data for a treatment of aneurysmal subarachnoid hemorrhages has a low probability of achieving statistical significance compared to the standard of care, according to Credit Suisse. 

As Edge has no other products in clinical development, this effectively eliminates its immediate revenue opportunity.

The best case scenario is a $2 valuation, Auster said. The worst case: zero. 

"Our grey sky valuation of zero assumes that EDGE spends through its remaining cash and is unable to obtain additional funding," Auster said. 

Despite continued cash burn for severance packages and trial closure costs, reductions in both R&D and general and administrative expenses are seen to improve the firm’s bottom-line prospects this year. Credit Suisse anticipates a 2018 loss per share of $1.45 against prior estimates of $2.21.

Price Action

Edge Therapeutics shares were down 6.5 percent at the time of publication Thursday. 

Related Links:

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

For Now, Traders Endorse Biotech Rally

Latest Ratings for EDGE

DateFirmActionFromTo
Mar 2018Credit SuisseDowngradesOutperformUnderperform
May 2016Credit SuisseMaintainsOutperform
Mar 2016Leerink SwannMaintainsOutperform

View More Analyst Ratings for EDGE
View the Latest Analyst Ratings

 

Related Articles (EDGE)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Martin AusterAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
CTASRBC CapitalMaintains360.0
MDTTruist SecuritiesMaintains120.0
ATEMaxim GroupInitiates Coverage On1.0
MNPRMaxim GroupInitiates Coverage On11.0
RDS/BScotiaBankInitiates Coverage On34.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com